Table 3 Association between patient-related variables and survival.
Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | |
Sex (female vs male) | 0.73 (0.48–1.13) | 0.16 | 0.62 (0.38–1.02) | 0.061 |
ECOG performance status 1–2 (vs PS 0) | 1.18 (0.77–1.81) | 0.44 | 1.28 (0.80–2.05) | 0.30 |
HCT-CI ≥ 3 (vs HCT-CI < 3) | 1.11 (0.73–1.68) | 0.61 | 0.91 (0.57–1.45) | 0.63 |
SPPB ≥ 9 (vs SPPB < 9) | 0.87 (0.57–1.31) | 0.50 | 0.85 (0.54–1.32) | 0.48 |
ADL index 6 (vs ADL < 6) | 1.08 (0.63–1.86) | 0.77 | 0.91 (0.49–1.68) | 0.76 |
Age > 76 years (vs ≤ 76) | 1.55 (1.02–2.34) | 0.039 | 1.58 (1.01–2.46) | 0.043 |
Diagnosis – (relative to primary AML) | ||||
- Secondary AML | 1.14 (0.69–1.86) | 0.61 | 1.21 (0.71–2.07) | 0.49 |
- MDS | 0.53 (0.28–0.99) | 0.048 | 0.45 (0.21–0.97) | 0.040 |
ELN 2017 risk – (relative to favorable) | ||||
- Intermediate | 0.68 (0.33–1.43) | 0.31 | 0.68 (0.32–1.46) | 0.32 |
- Adverse | 0.82 (0.48–1.41) | 0.47 | 0.71 (0.40–1.25) | 0.24 |
- MDS | 0.42 (0.20–0.89) | 0.023 | ||
